Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | Zendy

Gabriel N. Hortobágyi | Zendy; Salomon M. Stemmer | Zendy; Howard A. Burris | Zendy; Yoon Sim Yap | Zendy; Gabe S. Sonke | Zendy; Lowell L. Hart | Zendy; Mario Campone | Zendy; Katarína Petráková | Zendy; Eric P. Winer | Zendy; Wolfgang Janni | Zendy; Pierfranco Conté | Zendy; David Cameron | Zendy; Fabrice André | Zendy; Carlos L. Arteaga | Zendy; Juan Pablo Zarate | Zendy; Arunava Chakravartty | Zendy; Tetiana Taran | Zendy; Fabienne Le Gac | Zendy; Paolo Serra | Zendy; Joyce O’Shaughnessy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

Author(s) -

Gabriel N. Hortobágyi,

Salomon M. Stemmer,

Howard A. Burris,

Yoon Sim Yap,

Gabe S. Sonke,

Lowell L. Hart,

Mario Campone,

Katarína Petráková,

Eric P. Winer,

Wolfgang Janni,

Pierfranco Conté,

David Cameron,

Fabrice André,

Carlos L. Arteaga,

Juan Pablo Zarate,

Arunava Chakravartty,

Tetiana Taran,

Fabienne Le Gac,

Paolo Serra,

Joyce O’Shaughnessy

Publication year - 2022

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2114663

Subject(s) - letrozole , hazard ratio , medicine , breast cancer , placebo , oncology , clinical endpoint , confidence interval , progression free survival , aromatase inhibitor , cancer , randomized controlled trial , overall survival , tamoxifen , pathology , alternative medicine

In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Whether overall survival would also be longer with ribociclib was not known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research